Cingulate Inc. - Common Stock (CING)

Data Accepted as Finalist for First Annual Poster Awards

Werth Family Investment Associates Provides Additional Capital InvestmentPhase 3 Adult Efficacy and Safety Trial of CTx-1301 Data ReleasedCTx-1301 Phase 3 Pediatric and Adolescent Studies Underway

Results Indicative that CTx-1301 Provides Entire Active-Day Efficacy with Optimal Onset and Duration

Announcement Confirms Cingulate on Track with Development and Regulatory Milestones

Study Assessed Onset and Duration of CTx-1301 in Adults, Results Expected 3Q 2023

KANSAS CITY, Kan., May 25, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQCING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced it will participate in the 13th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel, Los Angeles, California, on June 6th-8th, 2023. The event is expected to feature 150+ companies, presenting in half-hour increments, as well as private one-on-one meetings.

KANSAS CITY, Kan., May 12, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQCING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Cingulate Chairman & CEO Shane J. Schaffer, and Timothy Moore, Indegene Senior Vice President, Emerging Biotech, will participate in a live Benzinga All Access event on Monday May 15, 2023, at 10 a.m. CST.

Additional $3 Million of Financing Proprietary PTR™ Manufacturing Processes Successfully Transferred to Societal CDMO Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301

Scalable Supply of CTx-1301 Ready to be Produced with Cingulate on Track to Meet Previously Announced Clinical Timelines for Phase 3 Trial Program

KANSAS CITY, Kan., April 14, 2023 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQCING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced that Chairman and CEO Shane J. Schaffer will participate in a live Benzinga All Access event on Tuesday April 18, 2023, at 10 a.m. CST.

Trial On Track for 3Q 2023 Results

Go-to-Market Solution Provides Full Commercial Support for the First, True Entire Active-Day Medication Designed to treat ADHD

Cingulate (NASDAQCING), is a biopharmaceutical company utilizing its proprietary PTR(TM) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of ADHD, Cingulate is identifying and evaluating additional therapeutic areas where PTR technology may be employed to develop future product candidates, including to treat anxiety disorders. Cingulate is headquartered in Kansas City. For more information, visit the company’s website at www.Cingulate.com .

NEW YORK, NY / ACCESSWIRE / December 10, 2021 / Aegis Capital Corp. acted as Lead Bookrunning Manager on a $25 Million Initial Public Offering of Common Stock for Cingulate Inc. (NASDAQCING). Cingulate Inc. Cingulate Inc. is a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products,